Rockville Newswire

Rockville Newswire

Comprehensive Real-Time News Feed for Rockville, MD.

Results 1 - 20 of 25 for "u:biospace.com" in Rockville, MD

  1. IDT Biologika Acquires Gallant Custom Laboratories Inc. , An...Read the original story

    Monday Aug 24 | BioSpace

    IDT Biologika announces today the acquisition of Gallant Custom Laboratories, based in Ontario, Canada. The transaction is to close August 31, 2015.

    Comment?

  2. REGENXBIO Files for $100 Milllion IPORead the original story

    Monday Aug 17 | BioSpace

    REGENXBIO, which is developing gene therapies for rare diseases and licensing out gene delivery technology, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The Rockville, MD-based company, which was founded in 2008 and booked $4 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol RGNX.

    Comment?

  3. Tivorsan Pharmaceuticals, Inc. Names Business Leader As CEO And Board MemberRead the original story

    Sunday Aug 16 | BioSpace

    Tivorsan Pharmaceuticals, Inc., a biotechnology company pioneering a novel approach to treating Duchenne Muscular Dystrophy and other serious neuromuscular disorders, today announced that James E. Connolly has joined the company as Chief Executive Officer and a member of the Board. Connolly is an accomplished business executive with more than 25 years of leadership roles in the pharmaceutical, biotechnology and non-profit sectors.

    Comment?

  4. Intrexon Corporation And Synthetic Biologics, Inc. Enter ECC To...Read the original story

    Sunday Aug 9 | BioSpace

    Collaboration Targets Delivery of an Essential Enzyme via ActoBioticsa Platform without Adverse Impact on Gut Microbiome GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ -- Intrexon Corporation , a leader in synthetic biology, and Synthetic Biologics, Inc. , a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria , a serious and debilitating metabolic disorder.

    Comment?

  5. Supernus Pharmaceuticals Announces Second Quarter 2015 Financial ResultsRead the original story

    Tuesday Aug 4 | BioSpace

    Second quarter product prescriptions totaled 91,324, representing a 99% increase over the same quarter last year and a 16% increase over the first quarter of 2015. Net product sales for the second quarter of 2015 were $34.3 million, representing a 24% increase over the same quarter last year and a 22% increase over the first quarter of 2015.

    Comment?

  6. Piccard Surgery Center And Blue Belt Technologies, Inc. Announce...Read the original story

    Jul 14, 2015 | BioSpace

    Piccard Surgery Center and Blue Belt Technologies announce today the addition of a Navio orthopedic surgical system to help surgeons perform precise and accurate partial knee replacement surgeries. The Navio system helps Piccard Surgery Center offer its patients one of the most advanced surgical technologies in Maryland.

    Comment?

  7. ABL Successfully Completes Drug Product Manufacture Of Ebola Vaccine For Clinical TrialRead the original story

    Jun 29, 2015 | BioSpace

    ABL, Inc. , a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. . "ABL's Phase I/II cGMP operations are designed to meet the needs of its client base, like EMERGENT, with flexible resourcing for small- and mid-scale production based on single-use, disposable platforms."

    Comment?

  8. Supernus Pharmaceuticals Announces Distribution Of Common Stock ByRead the original story

    Jun 16, 2015 | BioSpace

    ROCKVILLE, Md., June 17, 2015 -- Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice that, effective following the close of trading on June 15, 2015, New Enterprise Associates distributed an aggregate of 3,921,000 shares of Supernus Pharmaceuticals common stock to its partners. "It is not uncommon for a venture capital fund to distribute a portion of its position to its limited partners after holding that position for over nine years," stated Jack Khattar, president and chief executive officer of Supernus.

    Comment?

  9. REGENXBIO Enters Into Strategic Manufacturing Collaboration With WuXi AppTec, Inc.Read the original story

    Jun 10, 2015 | BioSpace

    REGENXBIO Inc ., a leading biotechnology company in gene therapy, today announced that it has entered into an exclusive strategic manufacturing collaboration with WuXi AppTec, Inc . WuXi is a leading technology platform company that provides clients with a broad and integrated portfolio of laboratory and manufacturing services, including expertise in characterization and analysis of biologics.

    Comment?

  10. The Coalition Of State Bioscience Institutes Announce The Winners Of...Read the original story

    May 27, 2015 | BioSpace

    The Coalition of State Bioscience Institutes , a group of non-profits organized to advance education, entrepreneurship and STEM workforce development, announced the winners of the STEM Voice video competition in collaboration with MdBio Foundation EDUCATE Center of the iBIO Institute and the Biocom Institute .

    Comment?

  11. Therabron Therapeutics Secures New Orphan Designation For The...Read the original story

    May 12, 2015 | BioSpace

    Therabron Therapeutics, Inc. , a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, today announced that the European Medicines Agency has granted the Company's lead product candidate, CG100, an orphan drug designation for the prevention of bronchopulmonary dysplasia . An orphan drug designation allows products receiving a marketing authorization from the EMA to have up to ten years of market exclusivity in the European Union .

    Comment?

  12. Supernus Pharmaceuticals Announces First Quarter 2015 Financial ResultsRead the original story

    May 5, 2015 | BioSpace

    Net product sales for the first quarter of 2015 were $28.1 million, compared to $9.0 million for the same quarter last year. First quarter product prescriptions totaled 78,763, representing a 146% increase over same quarter last year and an 11% increase over the fourth quarter of 2014.

    Comment?

  13. Canon U.S.A. Appoints President and CEO ofRead the original story

    May 4, 2015 | BioSpace

    Canon U.S.A., Inc., a leader in digital imaging solutions, today announced the appointment of Akiko Tanaka as president and CEO of Canon U.S. Life Sciences, Inc. , a wholly owned subsidiary of Canon U.S.A., Inc. Ms. Tanaka, previously the vice president and COO of CLS, has also been appointed to the CLS Board of Directors.

    Comment?

  14. MacroGenics, Inc. Announces Presentations At American Association for ...Read the original story

    Apr 16, 2015 | BioSpace

    ROCKVILLE, Md., April 16, 2015 -- MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that pre-clinical data from programs based on its Dual-Affinity Re-Targeting bi-specific technology will be presented at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA by the Company and Pfizer, Inc., one of MacroGenics' collaboration partners.

    Comment?

  15. Pharm Country Roars As New Poll Shows Renewed Support for BiotechRead the original story w/Photo

    Apr 5, 2015 | BioSpace

    April 6, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor News that U.K.-based GlaxoSmithKline filed a WARN letter with the state of Pennsylvania indicating another 150 people would be laid off in its commercial and research and development group near Philadelphia, and that it would simultaneously relocate another R&D unit to Maryland, has the community buzzing. In our most recent poll, BioSpace wanted to know if you think Pharm Country will do what it takes to keep biotech jobs in the area? The answer was a resounding yes, with 69 percent of the 307 respondents saying they believe that Pennsylvania officials will continue to offer tax breaks and other labor benefits to keep biotech booming in the region.

    Comment?

  16. GlaxoSmithKline Shifts Philly R&D Jobs to Maryland Vaccine Hub As Reorganization ContinuesRead the original story

    Apr 1, 2015 | BioSpace

    Drugmaker GlaxoSmithKline said Thursday that it will establish a new "hub" for vaccine research and development in the Washington, D.C., suburb of Rockville, Md., a move that will have direct impact on about 150 employees at the company's King of Prussia facility. Establishing the Maryland hub, GSK said in a statement, "will consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia and Cambridge, Mass., into one centralized location.

    Comment?

  17. Immunomic Therapeutics Receives Positive Feedback From FDA Following...Read the original story

    Mar 24, 2015 | BioSpace

    HERSHEY, Pa., and ROCKVILLE, Md., March 25, 2015 -- Immunomic Therapeutics, Inc., a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has concluded pre-IND discussions with the U.S. Food and Drug Administration regarding its proprietary ARA-LAMP-Vax vaccine currently under development for peanut allergies. The company received positive and helpful feedback, which it expects will be instrumental in designing its Phase 1 trials.

    Comment?

  18. Supernus Pharmaceuticals Announces Fourth Quarter And Full Year 2014 ResultsRead the original story

    Mar 10, 2015 | BioSpace

    Total revenue for the fourth quarter, $30.8 million, exceeded guidance by $4 million, and includes $30.5 million in net product sales. Met with the FDA in December to review SPN-810.

    Comment?

  19. Synthetic Biologics, Inc.' SYN-004 Data For Protection Of Microbiome...Read the original story

    Mar 10, 2015 | BioSpace

    "We are on schedule to initiate the Phase 2a clinical trial of SYN-004 this quarter, with a Phase 2b clinical trial anticipated to initiate during the second half of this year." The U.S. Centers for Disease Control and Prevention has categorized C. difficile as an "urgent public health threat," and has stated the need for research to better understand the role of normal gut bacteria.

    Comment?

  20. France's Chooses And To Accelerate Clinical Research By Analyzing...Read the original story

    Mar 8, 2015 | BioSpace

    SOURCE TEMIS Joint project will accelerate the constitution of relevant patient cohorts for clinical research ROCKVILLE, Maryland, March 9, 2015 /PRNewswire/ -- TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, today announced that its solution Luxid has been chosen by France's UNICANCER, the Federation of French Cancer Centers , as the semantic module for its ConSoRe project driven by SWORD Consulting and Services. Clinical Trials help progress the fight against cancer by validating promising treatments on actual patients.

    Comment?

Rockville Job Listings
View or post Rockville job listings on Topix.
Rockville Real Estate
News, listings, and foreclosures in Rockville from Topix.
Rockville Mortgages
Find mortgage rates in Rockville on Topix.